Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Developer Hadley Property Group has lodged a hybrid planning application to redevelop the flagship former GlaxoSmithKline ...

Hadley Property Group has submitted plans to transform GSK House, biopharma company GSK's former headquarters in west London, ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

Property developer Hadley Group has sent in its application for a 13-acre redevelopment of the former GSK headquarters in ...

Dividend shares are one way of taking the battle to rising inflation. Our writer picks out three FTSE 100 stocks that might ...

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

GSK PLC closed 14.28% short of its 52-week high of £16.79, which the company reached on September 9th.

Counterfeit and 'not of standard quality' drugs are more than a regulatory headache -- they erode patient trust, compromise ...